Sinclair Launches Sinclair Cares: Help Drive Out Cancer, Joins the American Cancer Society to Raise Awareness and Support Free Rides to Medical Treatment
As part of the initiative, Sinclair will produce content to air within its newscasts from July 14–27. In addition to news coverage, Sinclair stations will air a 30-minute special highlighting the American Cancer Society Road To Recovery® program on July 26/27, and which will stream on stations' websites on July 23. The Sinclair Cares: Help Drive Out Cancer special will feature interviews with volunteer drivers and people with cancer receiving treatment, sharing powerful stories that underscore the program's life-changing impact and the growing need for more community involvement.
The stations, and Tennis Channel, will also feature public service announcements and a robust social media campaign to share stories of impact and highlight ways the public can get involved including:
Volunteering to Drive: Learn how to become a Road To Recovery® driver and support people with cancer in your local community.
Donate: Contributions will help fund transportation, lodging and patient navigation services.
Get Help: For those currently facing transportation challenges, the campaign will provide resources to access American Cancer Society support.
'Through Sinclair Cares: Help Drive Out Cancer, we're proud to join with the American Cancer Society to shine a light on a critical but often overlooked issue—how something as simple as a ride can mean the difference between treatment and missed care,' said Rob Weisbord, COO and President of Local Media, Sinclair. 'We hope to inspire our viewers to take action, whether by donating, volunteering, or sharing the message.'
For more information on Sinclair Cares: Help Drive Out Cancer, including how to receive help, become a volunteer driver, or make a donation, visit www.SinclairCares.com.
About Sinclair Cares:
Sinclair Cares utilizes the strength of Sinclair Inc.'s properties to uplift organizations and inspire audiences and employees to make a positive impact in their communities. A company-wide initiative, Sinclair Cares mobilizes Sinclair's assets to support community and charitable endeavors through volunteerism, fundraising, and storytelling. Recent partnerships include The American Red Cross, Feeding America, Disabled American Veterans (DAV), NAMI, Reading is Fundamental, and The Salvation Army.
About Sinclair:
Sinclair, Inc. (Nasdaq: SBGI) is a diversified media company and a leading provider of local news and sports. The Company owns, operates and/or provides services to 185 television stations in 85 markets affiliated with all major broadcast networks; owns Tennis Channel, the premium destination for tennis enthusiasts; multicast networks CHARGE, Comet, ROAR and The Nest; and the nation's largest streaming aggregator of local news content, NewsON. Sinclair's AMP Media produces a growing portfolio of digital content and original podcasts. Additional information about Sinclair can be found at www.sbgi.net.
Category: General
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Acadia Healthcare Announces Date for Second Quarter 2025 Earnings Release
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2025 results on Tuesday, August 5, 2025, after the close of the market. Acadia will conduct a conference call with institutional investors and analysts at 9:00 a.m. ET on Wednesday, August 6, 2025. A live broadcast of the conference call will be available at in the 'Investors' section of the website. The webcast of the conference call will be available for 30 days. About Acadia Healthcare Acadia is a leading provider of behavioral healthcare services across the United States. As of March 31, 2025, Acadia operated a network of 270 behavioral healthcare facilities with approximately 12,000 beds in 39 states and Puerto Rico. With approximately 25,500 employees serving more than 82,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Newsweek
an hour ago
- Newsweek
Seven Questions for Miruna Sasu, Cancer Data and Research Guru
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Data is more important than ever before for health care organizations. In today's techy environment, hospitals and clinics can derive insights from vast patient records to deliver care more safely, effectively and efficiently. But patient data is often unstructured, and insights aren't always easy to glean—especially in specialties like oncology, where care records are particularly long and complex. That's where COTA Healthcare comes in. Its platform pulls data from electronic medical records at hospitals and clinics, cleans and adjudicates the clinical notes and then returns them to the health care organizations for cancer research and drug development purposes. That work has enormous potential, as the American Cancer Society estimates that more than 2 million new cancer cases will be diagnosed in 2025 alone. Despite the wide-ranging impacts, this mission is deeply personal for Miruna Sasu, the president and CEO of COTA Healthcare. Ahead of Newsweek's Women's Global Impact forum, Sasu told Newsweek how her work intertwines with her identity. Miruna Sasu is the president and CEO of COTA Healthcare and will be speaking at Newsweek's Women's Global Impact forum on August 5 in New York City. Miruna Sasu is the president and CEO of COTA Healthcare and will be speaking at Newsweek's Women's Global Impact forum on August 5 in New York City. Newsweek Illustration/Canva Newsweek: Walk me through your career trajectory. What sparked your interest in science / health care? Do you recall any formative experiences or mentors? Sasu: "The fight against cancer is personal for me. When I first moved to the U.S., my grandfather was diagnosed with Stage 4 lung cancer. Enrolling him in a clinical trial saved his life and gave us 35 more years with him. That time changed the course of my life. It allowed me to pursue my education and career, and it's a big part of why I do this work. The path to my current role has taken a few turns. I started in food safety with the federal government, then moved into life sciences at Bristol Myers Squibb, where I first worked with real-world data. I continued that work at Johnson & Johnson, focusing on making clinical trials more efficient. Eventually, I felt a strong pull to work entirely in cancer, which brought me to COTA. Along the way, I have been fortunate to have mentors who offered their time, insight and belief in me. Some of them recognized my leadership potential before I was ready to see it in myself. That kind of support shaped who I am and how I lead. It taught me to stay curious, to act with courage and to lead with empathy and purpose." What challenges did you face along the way, and what accomplishments are you most proud of? "There have been plenty of challenges. Change is hard, especially in health care. Most people care deeply about making a meaningful impact on patient outcomes, but org structures don't always make it easy. A lot of my work has focused on getting people aligned across departments and functions and on building trust so we can move forward together." What problems do you aim to solve in your current role? How do you measure progress toward your goals? "We are trying to solve a core problem in health care: how to use data to improve outcomes for patients. It's about making data not just available but actionable. We want to help pharma find the right patients for trials faster, support providers with better insights and ultimately help people get the care they need sooner." What are some recent projects or advancements that you're particularly excited about? "One of the most exciting developments at COTA is the launch of CAILIN, a new suite of AI-powered cancer data tools. For a long time, working with real-world data has required deep technical expertise and significant time to extract insights. CAILIN changes that by allowing users to ask complex research questions in plain language and receive answers within seconds. It also supports our medical abstractors by guiding them through the data curation process more efficiently, which helps improve both speed and quality. We are already seeing the impact of CAILIN across our work. Researchers, clinicians and life sciences teams can now access the insights they need without relying solely on data scientists. This kind of access accelerates decision-making and makes it easier for more people to work directly with high-quality oncology data. CAILIN is not a replacement for human expertise, but it is a powerful tool that helps us do more, faster. It is a meaningful step forward in cancer research, and I am incredibly proud of the team that made it possible." What are you most passionate about? Does your current role enable you to explore this passion? "I care deeply about using data to solve real-world problems. My passion lies in making health care more equitable, more effective and more humane. I'm also passionate about people. Building a healthy, inclusive team culture where people feel valued and motivated is something I work on just as intentionally as product or strategy. The two go hand in hand." Has being a woman shaped your leadership style and/or the way that you think about your work in the health care industry? "It has. Being a woman in leadership has taught me how to lead with both strength and empathy. I've had to work harder at times to prove myself, and that has made me more aware of how I show up and how I support others. I've learned to listen more, to trust my instincts and to lead with clarity. And I've made it a point to open doors for others wherever I can." Women make up 70% of the global health care workforce but hold just 25% of the industry's leadership positions. What do you make of this gender gap? How might we begin to close it? "It's a real gap, and it reflects long-standing structural issues, not a lack of qualified women. We need to be more intentional about creating pathways to leadership. That includes mentorship, sponsorship, fair hiring practices and making sure women have real opportunities to grow and lead. Representation also matters. When women see others leading at the highest levels, it expands what feels possible. I take that responsibility seriously and try to be the kind of leader I would have looked up to earlier in my own journey and to carve out paths for others to have an opportunity to do the same." Sasu will join Newsweek at this year's inaugural Women's Global Impact forum. The August 5 event, hosted at Newsweek's headquarters in New York City, will bring together some of the world's top female executives and connect them with rising stars across industries and job functions. For more information on the event, please visit the Women's Global Impact homepage.
Yahoo
2 hours ago
- Yahoo
Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
ORLANDO, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ('Nutriband' or the 'Company') is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend. Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August. 5th. Each preferred share will be convertible to one share of common stock following FDA approval of the Company's AVERSA Fentanyl product. If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an annual basis as decided by the board of Directors. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is Any material contained in or derived from the Company's websites or any other website is not part of this press release. Forward-Looking Statements Certain statements contained in this press release, including, without limitation, statements containing the words ''believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K's and Forms 10-Q's, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. Contact Information: Nutriband Inc. Phone: 407-377-6695 Email: info@ SOURCE: Nutriband in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
